ReviewClinical, cosmetic and investigational dermatology2025
Updates in the Treatment of Rosacea with γ-Aminobutyric Acid Derivatives.
Review in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Neurogenic Rosacea and Facial Dysesthesia: Neurovascular-Immune Mechanisms and Translational Therapeutic Perspectives.Medicina (Kaunas, Lithuania) · 2026Review
- Decoding the Neurological Connection Between Rosacea and Migraines: Exploring Shared Mechanisms.Cureus · 2026Review
- Neurohormonal-Immune Dysregulation in Rosacea: Emerging Perspectives from the Skin-Gut-Brain Axis.Drug design, development and therapy · 2026Review
- Therapeutic progress in rosacea: targeting the neuro-vascular-immune triad.Frontiers in immunology · 2026Review
- Calcitonin gene-related peptide promotes mast cell-mediated neuroimmune inflammation through the CALCRL/RAMP1-JAK3-STAT1 axis in rosacea.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurogenic inflammation plays an important role in the pathogenesis of rosacea. Recently, several clinical studies have found that γ-aminobutyric acid (GABA) derivatives can effectively improve the erythema and burning symptoms of rosacea. The underlying mechanisms may relate to the ability of GABA derivatives to inhibit the transient receptor potential channel pathway, subsequently reducing abnormal neuronal activation, inhibiting neuropeptide release, and suppressing neurogenic inflammation. This paper aimed to comprehensively review the progress of fundamental and clinical research on the role of neurogenic inflammation in the pathogenesis of rosacea and the application of GABA derivatives in rosacea treatment. We believe this paper will provide new directions for the treatment of rosacea. PubMed, China National Knowledge Infrastructure, and Web of Science databases were searched for relevant literature. The literature review revealed that GABA derivatives, such as pregabalin and gabapentin, may be effective in relieving the redness and erythema symptoms of rosacea. The potential mechanisms and the effects of GABA derivatives in rosacea treatment were reviewed, providing a new basis for the treatment of rosacea.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.